February 16, 2018 08:54 AM ESTUpdated 11:36 AM

The FDA raises hopes for Alzheimer's drugs with a new set of draft rules. But are they going too far?

Bioregnum

The view from John Carroll

For years now the gold standard for R&D in Alzheimer’s has focused on generating convincing evidence that …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

US warns drugmakers against misrepresenting cost of imported products

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

sponsored

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?